Efficacy and ADRs to the 105 exposures to biologics prescribed for relapsing polychondritis in 41 patients
| Exposures to biologics | Response achieved during the first 6 months , n (%) | CR achieved during the first 6 months , n (%) | Variation in CS dose at M6, mg PEQ, median (range)* | Follow-up, months, median (range) | Discontinuation of biologic | ||||
| Overall n (%) | Insufficient efficacy n (%) | Loss of efficacy n (%) | ADR n (%) | Stable CR | |||||
| Overall (n=105) | 66 (62.9) | 20 (19.0) | −5.0 (−72.5;+70.0) | 6.0 (0.1–80.8) | 77 (73.3) | 36 (34.3) | 19 (18.1) | 22 (20.9) | 1 (0.9) |
| TNF antagonists (n=60) | 38 (63.3) | 14 (23.3) | −5 (−53;+70) | 6.0 (0.4–80.8) | 47 (78.3) | 23 (38.3) | 15 (25.0) | 8 (13.3) | 1 (1.7) |
| Infliximab (n=20) | 12 (60.0) | 7 (35.0) | −5 (−50;+70) | 6.5 (0.4–80.8) | 16 (80.0) | 7 (35.0) | 6 (30.0) | 3 (15.0) | 0 |
| Adalimumab (n=25) | 16 (64.0) | 5 (20.0) | −7.5 (−53;+10) | 8.0 (0.4–71.7) | 18 (72.0) | 6 (24.0) | 7 (28.0) | 5 (20.0) | 1 (4.0) |
| Etanercept (n=11) | 8 (72.7) | 0 | −5 (−50;+0) | 5.5 (0.7–36.7) | 11 (100) | 8 (72.7) | 2 (18.2) | 2 (18.2) | 0 |
| Golimumab (n=3) | 2 (66.7) | 2 (66.7) | −20 | 3.8 (3.4–7.2) | 1 (33.3) | 1 (33.3) | 0 | 0 | 0 |
| Certolizumab (n=1) | 0 | 0 | − | 2.9 | 1 (100) | 1 (100) | 0 | 1 (100) | 0 |
| Tocilizumab (n=17) | 12 (70.6) | 2 (11.8) | −1 (−72.5;+0) | 3.7 (0.4–36.2) | 10 (58.8) | 4 (23.5) | 2 (11.7) | 4 (23.5) | 0 |
| Anakinra (n=15) | 8 (53.3) | 2 (13.3) | −12.5 (-20;+0) | 2.6 (0.3–63.8) | 13 (86.7) | 5 (33.3) | 0 | 7 (46.7) | 0 |
| Rituximab (n=7) | 5 (71.4) | 1 (14.3) | −3 (−30;+5) | 6.0 | 3 (42.8) | 3 (42.8) | 0 | 0 | 0 |
| Abatacept (n=6) | 3 (50.0) | 1 (16.7) | −16 (−40;+0) | 9.5 (0.1–37.1) | 6 (100) | 3 (50.0) | 2 (33.3) | 1 (16.7) | 0 |
*Data available for 13 patients on infliximab, 16 on adalimumab, 7 on etanercept, 1 on golimumab, none on certolizumab pegol, 4 on anakinra, 7 on rituximab, 10 on tocilizumab and 4 on abatacept.
ADR, adverse drug reaction; CR, complete response; CS, corticosteroids; PEQ, prednisone equivalent; TNF, tumour necrosis factor.